Green tea polyphenol epigallocatechi3-gallate: Inflammation and arthritis

Life Sciences

Volumn 86, Issue 25-26, 2010, Pages 907-918

  Singh, Rashmi ^a   Akhtar, Nahid ^b   Haqqi, Tariq M ^b  

^a BANARAS HINDU UNIVERSITY   (India)

^b METROHEALTH MEDICAL CENTER   (United States)

Author keywords

EGCG; Green Tea; MAPK; NF B; Osteoarthritis; Rheumatoid arthritis

Indexed keywords

AGGRECANASE 1; AGGRECANASE 2; BASIC FIBROBLAST GROWTH FACTOR; COLLAGENASE 3; CYCLOOXYGENASE 2; EPIGALLOCATECHIN GALLATE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; POLYPHENOL; PROSTAGLANDIN E2; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; CELL TYPE; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; INFLAMMATION; JOINT DESTRUCTION; NONHUMAN; OSTEOARTHRITIS; OXIDATIVE STRESS; PROTEOMICS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TEA;

ARTHRITIS; CATECHIN; FLAVONOIDS; HUMANS; INFLAMMATION; PHENOLS; STRUCTURE-ACTIVITY RELATIONSHIP; TEA;

ANIMALIA;

EID: 77953612514     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2010.04.013     Document Type: Review

References (162)

1. Ahmad N., Gupta S., Mukhtar H. Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor κB in cancer cells versus normal cells. Archives of Biochemistry and Biophysics 2000, 376(2):338-346.
2. Ahmed S., Rahman A., Hasnain A., Lalonde M., Goldberg V.M., Haqqi T.M. Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1 beta-induced activity and expression of cyclooxygenase-2 and nitric oxide synthase-2 in human chondrocytes. Free Radical Biology & Medicine 2002, 33(8):1097-1105.
3. Ahmed S., Pakozdi A., Koch A.E. Regulation of interleukin-1beta-induced chemokine production and matrix metalloproteinase 2 activation by epigallocatechin-3-gallate in rheumatoid arthritis synovial fibroblasts. Arthritis & Rheumatism 2003, 54(8):2393-2401.
4. Ahmed S., Wang N., Lalonde M., Goldberg V.M., Haqqi T.M. Green tea polyphenol epigallocatechin-3-gallate (EGCG) differentially inhibits interleukin-1 beta-induced expression of matrix metalloproteinase-1 and -13 in human chondrocytes. Journal of Pharmacology and Experimental Therapeutics 2004, 308(2):767-773.
5. Ahmed S., Anuntiyo J., Malemud C.J., Haqqi T.M. Biological basis for the use of botanicals in osteoarthritis and rheumatoid arthritis: A review. Evidence Based Complementary and Alternative Medicine 2005, 2(3):301-308.
6. Ahmed S., Pakozdi A., Koch A.E. Regulation of interleukin-1beta-induced chemokine production and matrix metalloproteinase 2 activation by epigallocatechin-3-gallate in rheumatoid arthritis synovial fibroblasts. Arthritis & Rheumatism 2006, 54(8):2393-2401.
7. Ahmed S., Marotte H., Kwan K., Ruth J.H., Campbell P.L., Rabquer B.J., Pakozdi A., Koch A.E. Epigallocatechin-3-gallate inhibits IL-6 synthesis and suppresses transsignaling by enhancing soluble gp130 production. Proceedings of National Academy of Science U S A 2008, 105(38):14692-14697.
8. Ahmed S., Silverman M.D., Marotte H., Kwan K., Matuszczak N., Koch A.E. Down-regulation of myeloid cell leukemia 1 by epigallocatechin-3-gallate sensitizes rheumatoid arthritis synovial fibroblasts to tumor necrosis factor alpha-induced apoptosis. Arthritis & Rheumatism 2009, 60(5):1282-1293.
9. Aktas O., Prozorovski T., Smorodchenko A., Savaskan N.E., Lauster R., Kloetzel P.M., Infante-Duarte C., Brocke S., Zipp F. Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. The Journal of Immunology 2004, 173(9):5794-5800.
10. Alkharfy K.M., Kellum J.A., Matzke G.R. Unintended immunomodulation: part II. Effects of pharmacological agents on cytokine activity. Shock 2000, 13(5):346-360.
11. Altman R.D. Practical considerations for the pharmacologic management of osteoarthritis. American Journal of Managed Care 2009, 15(8):S236-S243.
12. Andriamanalijaona R., Kypriotou M., Baugé C., Renard E., Legendre F., Raoudi M., Boumediene K., Gatto H., Monginoux P., Pujol J.P. Comparative effects of 2 antioxidants, selenomethionine and epigallocatechin-gallate, on catabolic and anabolic gene expression of articular chondrocytes. The Journal of Rheumatology 2005, 32(10):1958-1967.
13. Arden N., Nevitt M.C. Osteoarthritis: Epidemiology. Best Practice & Research: Clinical Rheumatology 2006, 20(1):3-25.
14. Bae J.Y., Choi J.S., Choi Y.J., Shin S.Y., Kang S.W., Han S.J., Kang Y.H. (-)Epigallocatechin gallate hampers collagen destruction and collagenase activation in ultraviolet-B-irradiated human dermal fibroblasts: Involvement of mitogen-activated protein kinase. Food and Chemical Toxicology 2008, 46(4):1298-1307.
15. Baker M.S., Feigan J., Lowther D.A. Chondrocyte antioxidant defences: The roles of catalase and glutathione peroxidase in protection against H2O2 dependent inhibition of proteoglycan biosynthesis. The Journal of Rheumatology 1988, 15(4):670-677.
16. Belitz D.H., Grosh W. Quimica de los Alientos 1997, Acribia, Zaragosa.
17. Bordoni A., Hrelia S., Angeloni C., Giordano E., Guarnieri C., Caldarera C.M., Biagi P.L. Green tea protection of hypoxia/reoxygenation injury in cultured cardiac cells. The Journal of Nutritional Biochemistry 2002, 13(2):103-111.
18. Borsiczky B., Szabó Z., Jaberansari M.T., Mack P.P., Röth E. Activated PMNs lead to oxidative stress on chondrocytes: A study of swine knees. Acta Orthopaedica Scandinavica 2003, 74(2):190-195.
19. Boumediene K., Conrozier T., Mathieu P., Richard M., Marcelli C., Vignon E., Pujol J.P. Decrease of cartilage transforming growth factor-beta receptor II expression in the rabbit experimental osteoarthritis - Potential role in cartilage breakdown. Osteoarthritis and Cartilage 1998, 6(2):146-149.
20. Braddock M., Quinn A. Targeting IL-1 in inflammatory disease: New opportunity for therapeutic intervention. Nature Review Drug Discovery 2004, 3:330-335.
21. Brown S.L., Greene M.H., Gershon S.K., Edwards E.T., Braun M.M. Tumor necrosis factor antagonist therapy and lymphoma development: Twenty-six cases reported to the Food and Drug Administration. Arthritis & Rheumatism 2002, 46(12):3151-3158.
22. Bruneton J. Pharmacognosie, Phytochimie, Plantes Medicina-les 2001, Technique et Documentation-Lavoisier, Paris.
23. Cabrera C., Giménez R., López M.C. Determination of tea components with antioxidant activity. Journal of Agriculture and Food Chemistry 2003, 51(15):4427-4435.
24. Cabrera C., Artacho R., Gimenez R. Beneficial effects of green tea - A review. Journal of the American College of Nutrition 2006, 25(2):79-99.
25. Chan M.M., Fong D., Ho C.T., Huang H.I. Inhibition of inducible nitric oxide synthase gene expression and enzyme activity by epigallocatechin gallate, a natural product from green tea. Biochemical Pharmacology 1997, 54(12):1281-1286.
26. Chan F.K., Cryer B., Goldstein J.L., Lanas A., Peura D.A., Scheiman J.M., Simon L.S., Singh G., Stillman M.J., Wilcox C.M., Berger M.F., Breazna A., Dodge W. A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract. The Journal of Rheumatology 2010, 37(1):167-174.
27. Cheng X.W., Kuzuya M., Kanda S., Maeda K., Sasaki T., Wang Q.L., Tamaya-Mori N., Shibata T., Iguchi A. Epigallocatechin-3-gallate binding to MMP-2 inhibits gelatinolytic activity without influencing the attachment to extracellular matrix proteins but enhances MMP-2 binding to TIMP-2. Archives of Biochemistry and Biophysics 2003, 415(1):126-132.
28. Cheng K.W., Wong C.C., Chao J., Lo C., Chen F., Chu I.K., Che C.M., Ho C.T., Wang M. Inhibition of mutagenic PhIP formation by epigallocatechin gallate via scavenging of phenylacetaldehyde. Molecular Nutrition & Food Research 2009, 53(6):716-725.
29. Choi E.M. Oxidative status of DBA/1J mice with type II collagen-induced arthritis. Journal of Applied Toxicology 2007, 27(5):472-481.
30. Chowdhury T.T., Salter D.M., Bader D.L., Lee D.A. Signal transduction pathways involving p38 MAPK, JNK, NFkappaB and AP-1 influences the response of chondrocytes cultured in agarose constructs to IL-1beta and dynamic compression. Inflammation Research 2008, 57(7):306-313.
31. Choy E.H., Isenberg D.A., Garrood T., Farrow S., Ioannou Y., Bird H., Cheung N., Williams B., Hazleman B., Price R., Yoshizaki K., Nishimoto N., Kishimoto T., Panayi G.S. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis & Rheumatism 2002, 46(12):3143-3150.
32. Chung J.Y., Huang C., Meng X., Dong Z., Yang C.S. Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in H-ras-transformed cells: Structure-activity relationship and mechanisms involved. Cancer Research 1999, 59(18):4610-4617.
33. Corps A.N., Curry V.A., Buttle D.J., Hazleman B.L., Riley G.P. Inhibition of interleukin-1beta-stimulated collagenase and stromelysin expression in human tendon fibroblasts by epigallocatechin gallate ester. Matrix Biology 2004, 23(3):163-169.
34. Costa L.M., Gouveia S.T., Nobrega J.A. Comparision of heating exraction procedures for Al, Ca, Mg and Mn in tea samples. Annals of Sciences 2002, 18:313-318.
35. Danesi F., Philpott M., Huebner C., Bordoni A., Ferguson L.R. Food-derived bioactives as potential regulators of the IL-12/IL-23 pathway implicated in inflammatory bowel diseases. Mutation Research 2010, [Electronic publication ahead of print].
36. de Hooge A.S., van de Loo F.A., Koenders M.I., Bennink M.B., Arntz O.J., Kolbe T., van den Berg W.B. Local activation of STAT-1 and STAT-3 in the inflamed synovium during zymosan-induced arthritis: Exacerbation of joint inflammation in STAT-1 gene-knockout mice. Arthritis & Rheumatism 2004, 50(6):2014-2023.
37. de Mejia E.G., Ramirez-Mares M.V., Puangpraphant S. Bioactive components of tea: Cancer, inflammation and behavior. Brain Behavior & Immunology 2009, 23(6):721-731.
38. De Rienzo F., Saxena P., Filomia F., Caselli G., Colace F., Stasi L., Giordani A., Menziani M.C. Progress towards the identification of new aggrecanase inhibitors. Current Medicinal Chemistry 2009, 16(19):2395-2415.
39. Doná M., Dell'Aica I., Calabrese F., Benelli R., Morini M., Albini A., Garbisa S. Neutrophil restraint by green tea: Inhibition of inflammation, associated angiogenesis, and pulmonary fibrosis. The Journal of Immunology 2003, 170(8):4335-4341.
40. East C.J., Stanton H., Golub S.B., Rogerson F.M., Fosang A.J. ADAMTS-5 deficiency does not block aggrecanolysis at preferred cleavage sites in the chondroitin sulfate-rich region of aggrecan. The Journal of Biological Chemistry 2007, 282(12):8632-8640.
41. Farrell A.J., Blake D.R., Palmer R.M., Moncada S. Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Annals of Rheumatic Diseases 1992, 51(11):1219-1222.
42. Feist E., Burmester G.R. Is tocilizumab in combination with traditional DMARDs safe and effective for patients with active RA?. Nature Clinical Practice Rheumatology 2009, 5(3):128-129.
43. Feldman M., Maini R.N. Anti-TNF - A therapy of rheumatoid arthritis: what have we learned. Annual Review of Immunology 2001, 19:163-169.
44. Frei B., Higdon J.V. Antioxidant activity of tea polyphenols in vivo: Evidence from animal studies. The Journal of Nutrition 2003, 133(10):3275S-3284S.
45. Fujiki H., Suganuma M., Kurusu M., Okabe S., Imayoshi Y., Taniguchi S., Yoshida T. New TNF-alpha releasing inhibitors as cancer preventive agents from traditional herbal medicine and combination cancer prevention study with EGCG and sulindac or tamoxifen. Mutation Research 2003, 523-524:119-125.
46. Gonzalez-Fuentes A.M., Green D.M., Rossen R.D., Ng B. Intra-articular hyaluronic acid increases cartilage breakdown biomarker in patients with knee osteoarthritis. Clinical Rheumatology 2010, [Electronic publication ahead of print].
47. Goodridge H.S., Harnett W., Liew F.Y., Harnett M.M. Differential regulation of interleukin-12 p40 and p35 induction via Erk mitogen-activated protein kinase-dependent and -independent mechanisms and the implications for bioactive IL-12 and IL-23 responses. Immunology 2003, 109(3):415-425.
48. Hafeez B.B., Ahmed S., Wang N., Gupta S., Zhang A., Haqqi T.M. Green tea polyphenols-induced apoptosis in human osteosarcoma SAOS-2 cells involves a caspase-dependent mechanism with downregulation of nuclear factor-kappaB. Toxicology and Applied Pharmacology 2006, 216(1):11-19.
49. Haqqi T.M., Anthony D.D., Gupta S., Ahmad N., Lee M.S., Kumar G.K., Mukhtar H. Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea. Proceedings of National Academy of Science U S A 1999, 96(8):4524-4529.
50. Hayashi K., Takai S., Matsushima-Nishiwaki R., Hanai Y., Kato K., Tokuda H., Kozawa O. (-)-Epigallocatechin gallate reduces transforming growth factor beta-stimulated HSP27 induction through the suppression of stress-activated protein kinase/c-Jun N-terminal kinase in osteoblasts. Life Sciences 2008, 82(19-20):1012-1017.
51. Helmick C.G., Felson D.T., Lawrence R.C., Gabriel S., Hirsch R., Kwoh C.K., Liang M.H., Kremers H.M., Mayes M.D., Merkel P.A., Pillemer S.R., Reveille J.D., Stone J.H. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I. Arthritis & Rheumatism 2007, 58(1):15-25.
52. Henrotin Y., Deby-Dupont G., Deby C., De Bruyn M., Lamy M., Franchimont P. Production of active oxygen species by isolated human chondrocytes. British Journal of Rheumatology 1993, 32(7):562-567.
53. Hommes D.W., Peppelenbosch M.P., Von Deventer S.J.H. Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets. Gut 2003, 52:144-151.
54. Hong M.H., Kim M.H., Chang H.J., Kim N.H., Shin B.A., Ahn B.W., Jung Y.D. (-)-Epigallocatechin-3-gallate inhibits monocyte chemotactic protein-1 expression in endothelial cells via blocking NF-kappaB signaling. Life Sciences 2007, 80(21):1957-1965.
55. Hosokawa Y., Hosokawa I., Ozaki K., Nakanishi T., Nakae H., Matsuo T. Catechins inhibit CXCL10 production from oncostatin M-stimulated human gingival fibroblasts. The Journal of Nutritional Biochemistry 2009, [Electronic publication ahead of print].
56. Hsiao F.Y., Tsai Y.W., Huang W.F. Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: A retrospective study of physician-patient pairs in Taiwan. Clinical Therapy 2009, 31(11):2618-2627.
57. Huang G.S., Tseng C.Y., Lee C.H., Su S.L., Lee H.S. Effects of (-)-epigallocatechin-3-gallate on cyclooxygenase 2, PGE(2), and IL-8 expression induced by IL-1beta in human synovial fibroblasts. Rheumatology International 2009, [Electronic publication ahead of print].
58. Ichikawa D., Matsui A., Imai M., Sonoda Y., Kasahara T. Effect of various catechins on the IL-12p40 production by murine peritoneal macrophages and a macrophage cell line, J774.1. Biological & Pharmaceutical Bulletin 2004, 27(9):1353-1358.
59. Igaz P., Toth S., Falus A. Biological and clinical signifi cance of the JAK-STAT pathway: Lessons from knockout mice. Inflammation Research 2001, 50:435-441.
60. Jaswal S., Mehta H.C., Sood A.K., Kaur J. Antioxidant status in rheumatoid arthritis and role of antioxidant therapy. Clinical Chemica Acta 2000, 338:123-129.
61. Johnson G.L., Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002, 298:1911-1916.
62. Johnson J.J., Bailey H.H., Mukhtar H. Green tea polyphenols for prostate cancer chemoprevention: A translational perspective. Phytomedicine 2010, 17(1):3-13.
63. Kalavacherla U.S., Ishaq M., Rao U.R., Sachindranath A., Hepsiba T. Malondialdehyde as a sensitive marker of inflammation in patients with rheumatoid arthritis. Journal of Association of Physicians India 1994, 42(10):775-776.
64. Karin M., Ben-Neriah Y. Phosphorylation meets ubiqutination: The control of NFκB activity. Annual Reviews of Immunology 2000, 18:621-626.
65. Kasperkovitz P.V., Verbeet N.L., Smeets T.J., van Rietschoten J.G., Kraan M.C. van der Pouw Kraan TC, Tak PP, Verweij CL. Activation of the STAT1 pathway in rheumatoid arthritis. Annals of Rheumatic Diseases 2004, 63(3):233-239.
66. Katiyar S.K., Afaq F., Azizuddin K., Mukhtar H. Inhibition of UVB-induced oxidative stress-mediated phosphorylation of mitogen-activated protein kinase signaling pathways in cultured human epidermal keratinocytes by green tea polyphenol (-)-epigallocatechin-3-gallate. Toxicology and Applied Pharmacology 2001, 176(2):110-117.
67. Kawai K., Tsuno N.H., Kitayama J., Okaji Y., Yazawa K., Asakage M., Hori N., Watanabe T., Takahashi K., Nagawa H. Epigallocatechin gallate attenuates adhesion and migration of CD8+ T cells by binding to CD11b. Journal of Allergy and Clinical Immunology 2004, 113(6):1211-1217.
68. Khan N., Mukhtar H. Multitargeted therapy of cancer by green tea polyphenols. Cancer Letters 2008, 269(2):269-280.
69. Kim I.B., Kim D.Y., Lee S.J., Sun M.J., Lee M.S., Li H., Cho J.J., Park C.S. Inhibition of IL-8 production by green tea polyphenols in human nasal fibroblasts and A549 epithelial cells. Biological & Pharmaceutical Bulletin 2006, 29(6):1120-1125.
70. Koeberle A., Bauer J., Verhoff M., Hoffmann M., Northoff H., Werz O. Green tea epigallocatechin-3-gallate inhibits microsomal prostaglandin E(2) synthase-1. Biochemical and Biophysics Research Communication 2009, 388(2):350-354.
71. Kraan P.M., Berg W.B. Anabolic and destructive mediators in osteoarthritis. Current Opinion in Clinical Nutrition & Metabolic Care 2000, 3:205-209.
72. Kurien B.T., Hensley K., Bachmann M., Scofield R.H. Oxidatively modified autoantigens in autoimmune diseases. Free Radical Biology & Medicine 2006, 41(4):549-556.
73. Lawrence R.C., Felson D.T., Helmick C.G., Arnold L.M., Choi H., Deyo R.A., Gabriel S., Hirsch R., Hochberg M.C., Hunder G.G., Jordan J.M., Katz J.N., Kremers H.M., Wolfe F. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part II. Arthritis & Rheumatism 2007, 58(1):26-35.
74. Lee D.M., Weinblatt M.E. Rheumatoid arthritis. Lancet 2001, 358:903-911.
75. Lee J.H., Chung J.H., Cho K.H. The effects of epigallocatechin-3-gallate on extracellular matrix metabolism. Journal of Dermatology Science 2005, 40(3):195-204.
76. Lee J.H., Chung K.Y., Bang D., Lee K.H. Searching for aging-related proteins in human dermal microvascular endothelial cells treated with anti-aging agents. Proteomics 2006, 6(4):1351-1361.
77. Lee A.S., Jung Y.J., Kim D.H., Lee T.H., Kang K.P., Lee S., Lee N.H., Sung M.J., Kwon D.Y., Park S.K., Kim W. Epigallocatechin-3-O-gallate decreases tumor necrosis factor-alpha-induced fractalkine expression in endothelial cells by suppressing NF-kappaB. Cell Physiology & Biochemistry 2009, 24(5-6):503-510.
78. Lee J.H., Jin H., Shim H.E., Kim H.N., Ha H., Lee Z.H. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal. Molecular Pharmacology 2010, 77(1):17-25.
79. Lin Y.L., Lin J.K. (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-kappaB. Molecular Pharmacology 1997, 52(3):465-472.
80. Lin S.K., Chang H.H., Chen Y.J., Wang C.C., Galson D.L., Hong C.Y., Kok S.H. Epigallocatechin-3-gallate diminishes CCL2 expression in human osteoblastic cells via up-regulation of phosphatidylinositol 3-Kinase/Akt/Raf-1 interaction: A potential therapeutic benefit for arthritis. Arthritis & Rheumatism 2008, 58(10):3145-3156.
81. Lin R.W., Chen C.H., Wang Y.H., Ho M.L., Hung S.H., Chen I.S., Wang G.J. (-)-Epigallocatechin gallate inhibition of osteoclastic differentiation via NF-kappaB. Biochemical and Biophysics Research Communication 2009, 379(4):1033-1037.
82. Lo Y.Y., Wong J.M., Cruz T.F. Reactive oxygen species mediate cytokine activation of c-Jun NH2-terminal kinases. The Journal of Biological Chemistry 1996, 271(26):15703-15707.
83. Loeser R.F. Chondrocyte integrin expression and function. Biorheology 2000, 37(1-2):109-116.
84. Loeser R.F. Integrins and cell signaling in chondrocytes. Biorheology 2002, 39(1-2):119-124.
85. Malemud C.J., Islam N., Haqqi T.M. Pathophysiological mechanisms in osteoarthritis lead to novel therapeutic strategies. Cells Tissues Organs 2003, 174(1-2):34-48.
86. Marotte H., Ruth J.H., Campbell P.L., Koch A.E., Ahmed S. Green tea extract inhibits chemokine production, but up-regulates chemokine receptor expression, in rheumatoid arthritis synovial fibroblasts and rat adjuvant-induced arthritis. Rheumatology (Oxford) 2009, 49(3):467-479.
87. McAlindon T.E., Jacques P., Zhang Y., Hannan M.T., Aliabadi P., Weissman B., Rush D., Levy D., Felson D.T. Do antioxidant micronutrients protect against the development and progression of knee osteoarthritis?. Arthritis & Rheumatism 1996, 39(4):648-656.
88. McInnes I.B., Liew F.Y. Cytokine networks - Towards new therapies for rheumatoid arthritis. Nature Clinical Practice & Rheumatology 2005, 1(1):31-39.
89. McKay D.L., Blumberg J.B. The role of tea in human health: An update. Journal of American College of Nutrition 2002, 21:1-13.
90. Melgarejo E., Medina M.A., Sánchez-Jiménez F., Urdiales J.L. Epigallocatechin gallate reduces human monocyte mobility and adhesion in vitro. British Journal of Pharmacology 2009, 58(7):1705-1712.
91. Menegazzi M., Tedeschi E., Dussin D., De Prati A.C., Cavalieri E., Mariotto S., Suzuki H. Anti-interferon gamma action of epigallocatechin-3-gallate mediated by specific inhibition of STAT1 activation. FASEB Journal 2001, 15(7):1309-1311.
92. Meng Q., Velalar C.N., Ruan R. Effects of epigallocatechin-3-gallate on mitochondrial integrity and antioxidative enzyme activity in the aging process of human fibroblast. Free Radical Biology & Medicine 2001, 44(6):1032-1041.
93. Minoia C., Sabbioni E., Ronchi A., Gatti A. Trace element reference values in tissues from inhabitants of the European Community. IV. Influence of dietary factors. Science of the Total Environment 1994, 141:181-195.
94. Mohammed F.F., Smookler D.S., Khokha R. Metalloproteinases, inflammation, and rheumatoid arthritis. Annals of Rheumatic Diseases 2003, 62(2):ii43-ii47.
95. Möller B., Villiger P.M. Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated inflammatory diseases. Springer Seminar in Immunopathology 2006, 27(4):391-408.
96. Moon H.S., Lee H.G., Choi Y.J., Kim T.G., Cho C.S. Proposed mechanisms of (-)-epigallocatechin-3-gallate for anti-obesity. Chemo Biological Interaction 2007, 167(2):85-98.
97. Morinobu A., Biao W., Tanaka S., Horiuchi M., Jun L., Tsuji G., Sakai Y., Kurosaka M., Kumagai S. (-)-Epigallocatechin-3-gallate suppresses osteoclast differentiation and ameliorates experimental arthritis in mice. Arthritis & Rheumatism 2008, 58(7):2012-2018.
98. Nakagawa K., Miyazawa T. Absorption and distribution of tea catechin, (-)-epigallocatechin-3-gallate, in the rat. Journal of Nutrition Science and Vitaminology (Tokyo) 1997, 43(6):679-684.
99. Nakagawa T., Yokozawa T. Direct scavenging of nitric oxide and superoxide by green tea. Food and Chemical Toxicology 2002, 40(12):1745-1750.
100. Nam S., Smith D.M., Dou Q.P. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. The Journal of Biological Chemistry 2001, 276(16):13322-13330.
101. Nelson J., McFerran N.V., Pivato G., Chambers E., Doherty C., Steele D., Timson D.J. The 67kDa laminin receptor: Structure, function and role in disease. Bioscience Reproducion 2008, 28(1):33-48.
102. Netsch M.I., Gutmann H., Aydogan C., Drewe J. Green tea extract induces interleukin-8 (IL-8) mRNA and protein expression but specifically inhibits IL-8 secretion in caco-2 cells. Planta Medicine 2006, 72(8):697-702.
103. Nie G., Jin C., Cao Y., Shen S., Zhao B. Distinct effects of tea catechins on 6-hydroxydopamine-induced apoptosis in PC12 cells. Archives of Biochemistry and Biophysics 2002, 397(1):84-90.
104. Nuti E., Casalini F., Avramova S.I., Santamaria S., Cercignani G., Marinelli L., La Pietra V., Novellino E., Orlandini E., Nencetti S., Tuccinardi T., Martinelli A., Lim N.H., Visse R., Nagase H., Rossello A. N-O-isopropyl sulfonamido-based hydroxamates: Design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis. Journal of Medicinal Chemistry 2009, 52(15):4757-4773.
105. Okamoto H., Cujec T.P., Yamanaka H., Kamatani N. Molecular aspects of rheumatoid arthritis: Role of transcription factors. FEBS Journal 2008, 275(18):4463-4470.
106. Osterburg A., Gardner J., Hyon S.H., Neely A., Babcock G. Highly antibiotic-resistant Acinetobacter baumannii clinical isolates are killed by the green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG). Clinical Microbiology and Infection 2009, 15(4):341-346.
107. Otero M., Goldring M.B. Cells of the synovium in rheumatoid arthritis. Chondrocytes. Arthritis Research & Therapy 2007, 9(5):220-226.
108. Park G., Yoon B.S., Moon J.H., Kim B., Jun E.K., Oh S. Green tea polyphenol epigallocatechin-3-gallate suppresses collagen production and proliferation in keloid fibroblasts via inhibition of the STAT3-signaling pathway. Journal of Investigative Dermatology 2008, 128:2429-2441.
109. Penm E, Dixon T, Bhatia K. Health expenditure for arthritis and musculoskeletal conditions in Australia, 2000-01. Australian Institute of Health and Welfare 2006, Bulletin no. 46 (catalogue no. AUS 83).
110. Plumb G.W., De Pascual-Teresa S., Santos-Buelga C., Cheynier V., Williamson G. Antioxidant properties of catechins and proanthocyanidins: Effect of polymerisation, galloylation and glycosylation. Free Radical Research 1998, 29(4):351-358.
111. Poduval P., Sillat T., Virtanen I., Dabagh M., Konttinen Y. Immigration check for neutrophils in RA lining: Laminin alpha5 low expression regions act as exit points. Scandinavian Journal of Rheumatology 2010, [Electronic publication ahead of print].
112. Porath D., Riegger C., Drewe J., Schwager J. Epigallocatechin-3-gallate impairs chemokine production in human colon epithelial cell lines. Journal of Pharmacology and Experimental Therapeutics 2005, 315(3):1172-1180.
113. Pujol J.P. TGF-beta and osteoarthritis: In vivo veritas?. Osteoarthritis and Cartilage 1999, 7(5):439-440.
114. Rasheed Z., Haqqi T.M. Updates on targets of biologic therapies for rheumatoid arthritis. Current Rheumatology Review 2008, 4:246-253.
115. Rasheed Z., Anbazhagan A.N., Akhtar N., Ramamurthy S., Voss F.R., Haqqi T.M. Green tea polyphenol epigallocatechin-3-gallate inhibits advanced glycation end product-induced expression of tumor necrosis factor-alpha and matrix metalloproteinase-13 in human chondrocytes. Arthritis Research & Therapy 2009, 11(3):R71.
116. Redlich K., Hayer S., Ricci R., David J.P., Tohidast-Akrad M., Kollias G., Steiner G., Smolen J.S., Wagner E.F., Schett G. Osteoclasts are essential for TNF-alpha-mediated joint destruction. The Journal of Clinical Investigation 2002, 110(10):1419-1427.
117. Richards P.J., Nowell M.A., Horiuchi S., McLoughlin R.M., Fielding C.A., Grau S. Functional characterization of a recombinant human soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis & Rheumatism 2006, 54:1662-1672.
118. Saeki K., Hayakawa S., Isemura M., Miyase T. Importance of a pyrogallol-type structure in catechin compounds for apoptosis-inducing activity. Phytochemistry 2000, 53(3):391-394.
119. Saklatvala J. Inflammatory signaling in cartilage: MAPK and NF-kappaB pathways in chondrocytes and the use of inhibitors for research into pathogenesis and therapy of osteoarthritis. Current Drug Targets 2007, 8(2):305-313.
120. Sato K., Takayanagi H. Osteoclasts, rheumatoid arthritis, and osteoimmunology. Current Opinion in Rheumatology 2006, 18(4):419-426.
121. Schett G., Tohidast-Akrad M., Smolen J.S. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis & Rheumatism 2000, 43:2501-2506.
122. Schneider C., Segre T. Green tea: Potential health benefits. American Family Physician 2009, 79(7):591-594.
123. Schwarz B., Bischof H.P., Kunze M. Coffee, tea and lifestyle. Preventive Medicine 1994, 23:377-384.
124. Seemüller E., Lupas A., Stock D., Löwe J., Huber R., Baumeister W. Proteasome from thermoplasma acidophilum: A threonine protease. Science 1995, 268(5210):579-582.
125. Serra R., Johnson M., Filvaroff E.H., LaBorde J., Sheehan D.M., Derynck R., Moses H.L. Expression of a truncated, kinase defective TGF-β type II receptor in mouse skeletal tissue promotes terminal chondrocyte differentiation and osteoarthritis. The Journal of Cell Biology 1997, 139:541-552.
126. Shen Y.J., Li W.G., Zhang H., Li B., Yuan H.X., Zhang J.J. Effects of (-)-epigallocatechin-3-gallate on interleukin-1beta expression in mouse wound healing. Fen Zi Xi Bao Sheng Wu Xue Bao 2009, 42(3-4):179-185.
127. Shin H.Y., Kim S.H., Jeong H.J., Kim S.Y., Shin T.Y., Um J.Y., Hong S.H., Kim H.M. Epigallocatechin-3-gallate inhibits secretion of TNF-alpha, IL-6 and IL-8 through the attenuation of ERK and NF-kappaB in HMC-1 cells. International Archives of Allergy and Immunology 2006, 142(4):335-344.
128. Singh R., Ahmed S., Islam N., Goldberg V.M., Haqqi T.M. Epigallocatechin-3-gallate inhibits interleukin-1beta-induced expression of nitric oxide synthase and production of nitric oxide in human chondrocytes: Suppression of nuclear factor kappaB activation by degradation of the inhibitor of nuclear factor kappaB. Arthritis & Rheumatism 2002, 46(8):2079-2086.
129. Singh R., Ahmed S., Malemud C.J., Goldberg V.M., Haqqi T.M. Epigallocatechin-3-gallate selectively inhibits interleukin-1beta-induced activation of mitogen activated protein kinase subgroup c-Jun N-terminal kinase in human osteoarthritis chondrocytes. Journal of Orthopedic Research 2003, 21(1):102-109.
130. Slack J., McMahan C.J., Waugh S., Schooley K., Spriggs M.K., Sims J.E., Dower S.K. Independent binding of interleukin-1 alpha and interleukin-1 beta to type I and type II interleukin-1 receptors. The Journal of Biological Chemistry 1993, 268(4):2513-2524.
131. Smith G.N. The role of collagenolytic matrix metalloproteinases in the loss of articular cartilage in osteoarthritis. Frontiers in Biosciences 2006, 11:3081-3095.
132. Smith A., Giunta B., Bickford P.C., Fountain M., Tan J., Shytle R.D. Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease. International Journal of Pharmacology 2010, [Electronic publication ahead of publication].
133. Song D.U., Jung Y.D., Chay K.O., Chung M.A., Lee K.H., Yang S.Y., Shin B.A., Ahn B.W. Effect of drinking green tea on age-associated accumulation of Maillard-type fluorescence and carbonyl groups in rat aortic and skin collagen. Archives of Biochemistry and Biophysics 2002, 397(2):424-429.
134. Sukhthankar M., Yamaguchi K., Lee S.H., McEntee M.F., Eling T.E., Hara Y., Baek S.J. A green tea component suppresses posttranslational expression of basic fibroblast growth factor in colorectal cancer. Gastroenterology 2008, 134(7):1972-1980.
135. Szekanecz Z., Koch A.E. Therapeutic inhibition of leukocyte recruitment in inflammatory diseases. Current Opinion in Pharmacology 2004, 4(4):423-428.
136. Tachibana H., Koga K., Fujimura Y., Yamada K. A receptor for green tea polyphenol EGCG. Nature Structural & Molecular Biology 2004, 11(4):380-381.
137. Takita H., Kikuchi M., Sato Y., Kuboki Y. Inhibition of BMP-induced ectopic bone formation by an antiangiogenic agent (epigallocatechin 3-gallate). Connective Tissue Research 2002, 43(2-3):520-523.
138. Tedeschi E., Suzuki H., Menegazzi M. Antiinflammatory action of EGCG, the main component of green tea, through STAT-1 inhibition. Annals of New York Academy of Science 2002, 973:435-437.
139. Teitelbaum S.L., Ross F.P. Genetic regulation of osteoclast development and function. Nature Review Genetics 2003, 4(8):638-649.
140. Tiku M.L., Gupta S., Deshmukh D.R. Aggrecan degradation in chondrocytes is mediated by reactive oxygen species and protected by antioxidants. Free Radical Research 1999, 30(5):395-405.
141. Tokuda H., Takai S., Matsushima-Nishiwaki R., Akamatsu S., Hanai Y., Hosoi T., Harada A., Ohta T., Kozawa O. (-)-epigallocatechin gallate enhances prostaglandin F2alpha-induced VEGF synthesis via upregulating SAPK/JNK activation in osteoblasts. Journal of Cellular Biochemistry 2007, 100(5):1146-1153.
142. Tokuda H., Takai S., Hanai Y., Matsushima-Nishiwaki R., Yamauchi J., Harada A., Hosoi T., Ohta T., Kozawa O. (-)-Epigallocatechin gallate inhibits basic fibroblast growth factor-stimulated interleukin-6 synthesis in osteoblasts. Hormone and Metabolic Research 2008, 40(10):674-678.
143. Townsend P.A., Scarabelli T.M., Pasini E., Gitti G., Menegazzi M., Suzuki H., Knight R.A., Latchman D.S., Stephanou A. Epigallocatechin-3-gallate inhibits STAT-1 activation and protects cardiac myocytes from ischemia/reperfusion-induced apoptosis. FASEB Journal 2004, 18(13):1621-1623.
144. Ullmann U., Haller J., Decourt J.P., Girault N., Girault J., Richard-Caudron A.S. A single ascending dose study of epigallocatechin gallate in healthy volunteers. Journal of International Medical Research 2003, 31:88-101.
145. vander-Kraan W.B., vanden-Berg P.M. Anabolic and destructive mediators in osteoarthritis. Current Opinion in Clinical Nutrition & Metabolic Care 2000, 3(3):205-211.
146. vanhet Hof K.H., Wiseman S.A., Yang C.S., Tijburg L.B. Plasma and lipoprotein levels of tea catechins following repeated tea consumption. Proceedings of the Society of Experimental Biology and Medicine 1999, 220(4):203-209.
147. Vankemmelbeke M.N., Jones G.C., Fowles C., Ilic M.Z., Handley C.J., Day A.J., Knight C.G., Mort J.S., Buttle D.J. Selective inhibition of ADAMTS-1, -4 and -5 by catechin gallate esters. European Journal of Biochemistry 2003, 270(11):2394-2403.
148. Warstat K., Hoberg M., Rudert M., Tsui S., Pap T., Angres B., Essl M., Smith T.J., Cruikshank W.W., Klein G., Gay S. Aicher WK.Transforming growth factor beta1 and laminin-111 cooperate in the induction of interleukin-16 expression in synovial fibroblasts from patients with rheumatoid arthritis. Annals of Rheumatic Diseases 2010, 69(1):270-275.
149. Weinreb O., Amit T., Youdim M.B. A novel approach of proteomics and transcriptomics to study the mechanism of action of the antioxidant-iron chelator green tea polyphenol (-)-epigallocatechin-3-gallate. Free Radical Biology & Medicine 2007, 43(4):546-556.
150. Westacott C.I., Sharif M. Cytokines in osteoarthritis: Mediators or markers of joint destruction?. Seminars in Arthritis and Rheumatism 1996, 25(4):254-272.
151. Wheeler D.S., Catravas J.D., Odoms K., Denenberg A., Malhotra V., Wong H.R. Epigallocatechin-3-gallate, a green tea-derived polyphenol, inhibits IL-1 beta-dependent proinflammatory signal transduction in cultured respiratory epithelial cells. The Journal of Nutrition 2004, 134(5):1039-1044.
152. Willson K.C. Coffee, Cocoa and tea 1999, CABI Publishing, New York.
153. Wu D., Guo Z., Ren Z., Guo W., Meydani S.N. Green tea EGCG suppresses T cell proliferation through impairment of IL-2/IL-2 receptor signaling. Free Radical Biology & Medicine 2009, 47(5):636-643.
154. Wu H., Qi H., Iwasaki D., Zhu B., Shimoishi Y., Murata Y., Nakamura Y. JNK-dependent NFATc1 pathway positively regulates IL-13 gene expression induced by (-)-epigallocatechin-3-gallate in human basophilic KU812 cells. Free Radical Biology & Medicine 2009, 47(7):1028-1038.
155. Xiao X., Yang Z.Q., Shi L.Q., Liu J., Chen W. Antiviral effect of epigallocatechin gallate (EGCG) on influenza A virus. Zhongguo Zhong Yao Za Zhi 2008, 3(22):2678-2682.
156. Yang F., de Villiers W.J., McClain C.J., Varilek G.W. Green tea polyphenols block endotoxin-induced tumor necrosis factor-production and lethality in a murine model. The Journal of Nutrition 1998, 128(12):2334-2340.
157. Yang F., Oz H.S., Barve S., de Villiers W.J., McClain C.J., Varilek G.W. The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-kappa B activation by inhibiting I kappa B kinase activity in the intestinal epithelial cell line IEC-6. Molecular Pharmacology 2001, 60(3):528-533.
158. Yokota A., Narazaki M., Shima Y., Murata N., Tanaka T., Suemura M., Yoshizaki K., Fujiwara H., Tsuyuguchi I., Kishimoto T. Preferential and persistent activation of the STAT1 pathway in rheumatoid synovial fluid cells. The Journal of Rheumatology 2001, 28(9):1952-1959.
159. Yun H.J., Yoo W.H., Han M.K., Lee Y.R., Kim J.S., Lee S.I. Epigallocatechin-3-gallate suppresses TNF-alpha -induced production of MMP-1 and -3 in rheumatoid arthritis synovial fibroblasts. Rheumatology International 2008, 29(1):23-29.
160. Zhang Z.F., Li Q., Liang J., Dai X.Q., Ding Y., Wang J.B., Li Y. Epigallocatechin-3-O-gallate (EGCG) protects the insulin sensitivity in rat L6 muscle cells exposed to dexamethasone condition. Phytomedicine 2010, 17(1):14-18.
161. Zheng W., Li R., Pan H., He D., Xu R., Guo T.B., Guo Y., Zhang J.Z. Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1beta through the NF-kappaB and MAPK pathways in rheumatoid arthritis. Arthritis & Rheumatism 2009, 60(7):1957-1965.
162. Zuo Y., Chen H., Deng Y. Simultaneous detection of the catechin, caffeine and gallic acid in green tea, oolong, black and pu-erh teas using HPLC with a photodiode array detector. Talanta 2002, 57:307-315.